羟苯磺酸钙联合康柏西普治疗视网膜静脉阻塞继发黄斑水肿的临床效果

Curative Effect of Calcium Dobesilate Combined with Conbercept in the Treatment of Macular Edema Secondary to Retinal Vein Occlusion

目的:探讨羟苯磺酸钙联合康柏西普治疗视网膜静脉阻塞继发黄斑水肿的临床效果。方法:选取我院2018年1月至2020年12月收治的84例(84眼)视网膜静脉阻塞继发黄斑水肿患者作为研究对象,随机分为对照组和观察组,各组42例(42眼)。对照组实施玻璃体腔内注射康柏西普联合安慰剂治疗,观察组实施玻璃体腔内注射康柏西普联合羟苯磺酸钙胶囊治疗;观察患眼治疗前、后最佳矫正视力(BCVA)和黄斑中心凹视网膜厚度(CMT)的变化及并发症发生情况。结果:治疗后各时间点,两组患者BCVA均比治疗前提高,且对照组低于观察组(P<0.05);治疗后各时间点,两组患者CMT比治疗前明显减小,且对照组高于观察组(P<0.05);两组患者均未出现严重并发症。结论:羟苯磺酸钙联合康柏西普治疗视网膜静脉阻塞继发黄斑水肿比单一使用康柏西普治疗的效果更好,能够更好地改善患者视力,更明显的降低CMT。

Objective:To investigate the clinical effect of calcium dobesilate combined with conbercept in the treatment of macular edema secondary to retinal vein occlusion.Methods:A total of 84 patients(84 eyes)with macular edema secondary to retinal vein occlusion admitted in our hospital from January 2018 to December 2020 were selected as the study objects and divided into control group and observation group according to random table and blind method,with 42 patients(42 eyes)in each group.The control group was treated with intravitreal injection of conbercept combined with placebo,while the observation group was treated with intravitreal injection of conbercept combined with calcium dobesilate capsules.BCVA and CMT were compared between the two groups at different time points,and the incidences of complications were recorded.Results:After 2 and 3 months of treatment,the BCVA of the two groups were higher than that before treatment,and those in the observation group were higher than the control group(P<0.05);after 2 and 3 months of treatment,CMT of the two groups were less than that before treatment,and those of the observation group were smaller than the control group(P<0.05).There were no serious complications occurred in both groups.Conclusion:Compared with conbercept alone,calcium dobesilate combined with conbercept has better effect on macular edema secondary to retinal vein occlusion,which can reduce CMT and improve the visual acuity of patients.